Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCRT vs SCRT Combined With CAPOX, Serplulimab and Celecoxib in MSS Locally Advanced Rectal Cancer
NCT07154316Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Immune Checkpoint Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of serplulimab and celecoxib in rectal adenocarcinoma (2 arms), sponsored by Fudan University. Primary endpoint: Complete Response at 3 years. Started Aug 2025; status: recruiting.
02
Drugs
serplulimabcelecoxib
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT07154316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154316.